Hallmarks of a lethal form of ovarian cancer called “high-grade serous ovarian carcinoma” (HGSOC) are an immunosuppressive tumor microenvironment, insensitivity to checkpoint inhibitor immunotherapies, and elevated expression of checkpoint pathway ligands that thwart the immune system’s ability to kill tumor cells. Nearly 70% of HGSOC tumors express PTK2, a gene that encodes FAK (focal adhesion kinase), elevated levels of which signal poor survival outcomes.
In a study published in the journal Proceedings of the National Academy of Sciences (“Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis”), scientists from the University of California (UC), San Diego, School of Medicine, Moores Cancer Center at UC San Diego Health, La Jolla Institute for Immunology, and their collaborators have demonstrated how key proteins act together to suppress antitumor activity in HGSOC, revealing a new combinatorial strategy to treat this intractable malignancy.
“Ovarian cancer is one of oncology’s greatest challenges,” said David Schlaepfer, PhD, a professor in the department of obstetrics, gynecology, and reproductive sciences at UC San Diego School of Medicine and senior author of the study. “Tumors can develop without obvious symptoms. The most common sign of ovarian cancer is abdominal swelling when the disease is advanced, which is when most women are diagnosed.”
Ovarian cancer is the fifth leading cause of cancer deaths among women and the majority of these cases are HGSOC tumors, according to the American Cancer Society.
Using transcriptomic analysis of ovarian cancer databases, an aggressive mouse ovarian tumor model, and multiplex immunofluorescence assays, the researchers demonstrated that FAK activation regulates CD155 expression, which is a checkpoint ligand for a T cell immunoreceptor called TIGIT. Based on this mechanistic discovery they found that combining an oral FAK inhibitor and a TIGIT antibody that blocks the immunoreceptor’s function, generated a significant antitumor response and increased survival time of a mouse model of the lethal cancer.
“In HGSOC tumors, where high levels of CD155 and active FAK are common, our results provide compelling support for targeting FAK and TIGIT as part of a new immune-boosting therapeutic strategy,” said Schlaepfer.
Immunotherapy is a treatment strategy that uses a person’s own immune cells to fight malignancy and has been successfully used to treat a variety of cancers, but it has not been effective in treating HGSOC.
Immune checkpoints constitute key regulatory steps in mounting an immune response. Inhibiting checkpoint receptors release the brakes of this stringent regulatory mechanism, allowing immune cells to engage in antitumor activity. HGSOC cells actively evade immune attacks by creating an immune-suppressive microenvironment.
Lead author of this study, Duygu Ozmadenci, PhD, a postdoctoral researcher in Schlaepfer’s lab, and his collaborators showed that active, phosphorylated FAK increased in late-stage HGSOC tumors and colocalized with CD155 in HGSOC tumors. They also showed HGSOC tumors with high FAK expression expressed low levels of CD3 transcripts that mark T cells that tumor infiltrate tumors.
An analysis of a patient transcriptomic database, and in vitro and in vivo experiments supported a selective binding between FAK and TIGIT checkpoint ligands. Through high levels of CD155, the tumor builds a safe environment for cancer cells to grow and evade immune detection and attack.
The researchers treated a mouse model of ovarian cancer with an oral anti-FAK drug and demonstrated reduced CD155 and other checkpoint proteins.
“We used a newly derived murine tumor model termed KMF (Kras, Myc, FAK amplified) as an aggressive platinum-resistant tumor model in immune-competent mice to show that genetic or pharmacological FAK inhibition resulted in the recruitment and activation of T cells,” said Schlaepfer.
In combination with a TIGIT-blocking antibody, the oral anti-FAK drug resulted in immune cell activation and tertiary lymphoid structure formation that mark a positive antitumor immune response. This in turn resulted in smaller tumors and prolonged survival of the mouse model.
Schlaepfer noted that several companies are testing FAK inhibitors and TIGIT immunotherapy, while this study provides the rationale for a combined immunotherapy. Schlaepfer’s team intends to conduct clinical trials of oral FAK inhibitors with anti-TIGIT blocking antibodies. He said, “Translational studies incorporating the testing of putative biomarkers are not only logical, but also feasible given the combinatorial potential of FAK inhibitors and antibody therapies targeting the CD155/TIGIT axis currently in clinical trials.”